title: Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
abstract: OBJECTIVE
  To determine whether pretreatment with dutasteride, a dual 5alpha-reductase inhibitor (5ARI), reduces surgical blood loss or postoperative complications in patients with benign prostatic hyperplasia (BPH) who undergo transurethral resection of the prostate (TURP).
  
  
  METHODS
  This double-blind, randomized, placebo-controlled, multicentre study comprised 214 patients with BPH. Placebo was compared with dutasteride 0.5 mg/day 2 weeks before and after TURP, or 4 weeks before and 2 weeks after TURP. Surgical blood loss was measured using a haemoglobin photometer (HemoCue AB, Angelholm, Sweden) and postoperative adverse events were recorded. Microvessel density (MVD) was calculated by immunostaining and light microscopy of the prostatic chips.
  
  
  RESULTS
  Although dutasteride reduced serum dihydrotestosterone (DHT) by 86-89% in 2-4 weeks, and intraprostatic DHT was approximately 10 times lower than in the placebo group, the (adjusted) mean haemoglobin (Hb) loss during surgery was 2.15-2.55 g Hb/g resectate with no significant difference in blood loss between the groups either during or after TURP. Clot retention occurred in 6-11% and urinary incontinence in 14-15% of patients during the 14 weeks after TURP, with no difference between the groups. The MVD at TURP was also similar for all groups.
  
  
  CONCLUSIONS
  There were no significant reductions in blood loss during or after TURP or complications afterward with dutasteride compared with placebo, despite significant suppression of intraprostatic DHT. Blood loss and transfusion rates in the placebo group were lower than those previously reported in studies where there was a beneficial effect of a 5ARI, relative to placebo, on bleeding during TURP.
authors.affiliation: Department of Anaesthesia, South Hospital, 118 83 Stockholm, Sweden. r.hahn@telia.com
authors.forename: Robert G
authors.initials: RG
authors.lastname: Hahn
authors.forename: Tim
authors.initials: T
authors.lastname: Fagerström
authors.forename: Teuvo L J
authors.initials: TL
authors.lastname: Tammela
authors.forename: Oncko
authors.initials: O
authors.lastname: Van Vierssen Trip
authors.forename: Hans Olav
authors.initials: HO
authors.lastname: Beisland
authors.forename: Annette
authors.initials: A
authors.lastname: Duggan
authors.forename: Betsy
authors.initials: B
authors.lastname: Morrill
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001378:Azasteroids / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D004311:Double-Blind Method; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care / Q000379:methods; D011470:Prostatic Hyperplasia / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D001378:Azasteroids; D004791:Enzyme Inhibitors; D000068538:Dutasteride